Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FOLFOXIRI Plus Bevacizumab as First-line Treatment for BRAF V600E Mutant Metastatic Colorectal Cancer: a Prospective Evaluation

NCT01437618 is registered in ClinicalTrials.gov with Azienda Ospedaliero, Universitaria Pisana as lead sponsor.

NCT NCT01437618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01437618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FOLFOXIRI Plus Bevacizumab as First-line Treatment for BRAF V600E Mutant Metastatic Colorectal Cancer: a Prospective Evaluation
Lead sponsor
Azienda Ospedaliero, Universitaria Pisana
Phase
Observational
Overall status
Completed
Start date
June 30, 2009
Completion date
May 31, 2011
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer